Sage CEO Planning to Launch New Postpartum Drug in 2019

The transcript discusses the positive results of SAGE 217, an oral antidepressant for postpartum depression, and its potential for treating other depression disorders. The company plans to seek FDA approval and discusses pricing strategies. SAGE is focused on growth, with several drugs in development and a strong market potential.

What pricing range was indicated for the drug Brexanolone?

What future developments can be expected from the company in the next six months?

What challenges does the company face regarding R&D spending versus profitability?